Atlas Trials

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Clinical trial NCT00012298 · TERMINATED

Trial details

NCT number
NCT00012298
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaSplenic Marginal Zone LymphomaWaldenström Macroglobulinemia
Start date
2001-04-01
Primary completion
2010-04-01
Enrollment
81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.